Concepedia

Haifeng Cui

HC

Statistics

Publications

17

Citations

801

H-Index

13

Active since

2006

Affiliations

GlaxoSmithKline (United States)(Current)

Chongqing Medical University

GlaxoSmithKline (United Kingdom)

First People's Hospital of Chongqing

China Academy of Chinese Medical Sciences

Haifeng Cui is an author at GlaxoSmithKline (United States) specializing in pharmacology, pharmacy, and drug discovery.

Publications per year

2006–2022

17

Publications

17

Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin

Pan F. Chan, Srikannathasan Velupillai, Jianzhong Huang et al. · Nature Communications · 2015 · 159 citations · Full text

, , +14

Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors

Krista Goodman, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 156 citations · Full text

, , +17

Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase

Pan F. Chan, Thomas Germe, B.D. Bax et al. · Proceedings of the National Academy of Sciences · 2017 · 84 citations · Full text

, , +17

Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 71 citations · Full text

, , +17

Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors

Steven T. Staben, Jianwen A. Feng, Karen S. Lyle et al. · Journal of Medicinal Chemistry · 2014 · 65 citations · Full text

, , +17

1–5 of 17